Loading…
eDrugstore was cited for unlawfully selling unapproved and misbranded compounded tirzepatide drugs over the internet by falsely claiming they were "FDA-approved formulations" and equating them to the FDA-approved product Zepbound. The company violated the Federal Food, Drug, and Cosmetic Act sections 502(a) and 502(bb) by making false or misleading claims in their website advertising that implied their compounded products were equivalent to approved drugs, when compounded drugs are not FDA-approved. This misbranding resulted in the unlawful introduction of these products into interstate commerce.